<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052088</url>
  </required_header>
  <id_info>
    <org_study_id>MM-1006-AP</org_study_id>
    <nct_id>NCT03052088</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients</brief_title>
  <acronym>AutoPilot</acronym>
  <official_title>A Multi-center, Prospective, Pilot Study to Validate the Diagnostic Accuracy and Assess the Potential Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the Emergency Department With Respiratory Tract Infection (RTI) or Fever Without Source (FWS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeMed Diagnostics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MeMed Diagnostics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical validation study of a novel regulatory approved (CE-IVD)&#xD;
      diagnostic assay called ImmunoXpert™ that will enroll 1222 pediatric patients. The study aims&#xD;
      to externally validate the tool's diagnostic accuracy and estimate the potential improvement&#xD;
      in health and economic outcomes following the usage of ImmunoXpert™. Additionally,&#xD;
      statistical analysis will be performed to compare ImmunoXpert™ accuracy to current practice&#xD;
      lab testing (e.g. WBC, CRP, and PCT) and clinical suspicion at time of requisition. Enrolled&#xD;
      patients will be managed according to the current standard of care and per standard&#xD;
      institutional procedures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To validate the diagnostic accuracy and assess the clinical utility of a host-response based diagnostic tool, for differentiating between bacterial and viral etiologies in pediatric patients &gt;90 days old with suspicion of RTI or FWS</measure>
    <time_frame>0-7 days after the initiation of symptoms</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the diagnostic accuracy of a host-response based diagnostic to currently available lab measures (WBC, ANC, CRP and PCT), using sensitivity and specificity measures and predetermined cutoffs</measure>
    <time_frame>0-7 days after the initiation of symptoms</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare ImmunoXpert™ results with the physician suspected diagnosis at time of patient recruitment and compared to the reference standard diagnosis</measure>
    <time_frame>0-7 days after the initiation of symptoms</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1140</enrollment>
  <condition>Fever</condition>
  <condition>Respiratory Tract Infections</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible subjects from both genders that present to the ED due to suspected RTI, or FWS.&#xD;
        Each of these patients falls into one of the following categories:&#xD;
&#xD;
          1. Patients with an acute bacterial infection&#xD;
&#xD;
          2. Patients with an acute viral infection&#xD;
&#xD;
          3. Patients with an acute co-infection (bacterial and viral)&#xD;
&#xD;
          4. Patients with an undetermined disease etiology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Legal guardian signs an informed consent&#xD;
&#xD;
          -  Documented peak temperature ≥ 38°C (100.4°F)&#xD;
&#xD;
          -  Symptom duration ≤ 7 days&#xD;
&#xD;
          -  Clinical suspicion of RTI (OR) fever without a clear source after clinical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another episode of febrile infection within the past 2 weeks&#xD;
&#xD;
          -  Antibiotic treatment of over 48 hours&#xD;
&#xD;
          -  Congenital immune deficiency (CID)&#xD;
&#xD;
          -  A proven or suspected HIV, HBV, HCV infection&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Current treatment with immune-suppressive or immune-modulating therapies, including&#xD;
             without limitations:&#xD;
&#xD;
          -  Use of high dose steroids &gt;1 mg/kg/day prednisone or equivalent in the past two weeks&#xD;
&#xD;
          -  Monoclonal antibodies, anti-TNF agents&#xD;
&#xD;
          -  Intravenous immunoglobulin (IVIG)&#xD;
&#xD;
          -  Cyclosporine, Cyclophosphamide, Tacrolimus&#xD;
&#xD;
          -  G/GM-CSF, Interferons&#xD;
&#xD;
          -  Other severe illnesses that affect life expectancy and/or quality of life such as:&#xD;
&#xD;
          -  Severe psychomotor retardation&#xD;
&#xD;
          -  Post-transplant patients&#xD;
&#xD;
          -  Severe congential metabolic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Tenenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinderklinik Universitatsmedizine mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinderklinik Universitatsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pietro Barilla Children's Hospital</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R, Wolchinsky R, Denkberg G, Dotan Y, Hochberg A, Reiter Y, Grupper M, Srugo I, Feigin P, Gorfine M, Chistyakov I, Dagan R, Klein A, Potasman I, Eden E. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One. 2015 Mar 18;10(3):e0120012. doi: 10.1371/journal.pone.0120012. eCollection 2015.</citation>
    <PMID>25785720</PMID>
  </reference>
  <reference>
    <citation>Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, Bamberger E, Klein A, Oved K. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug;73(2):177-80. doi: 10.1016/j.jinf.2016.05.002. Epub 2016 May 30.</citation>
    <PMID>27255416</PMID>
  </reference>
  <reference>
    <citation>van Houten CB, de Groot JAH, Klein A, Srugo I, Chistyakov I, de Waal W, Meijssen CB, Avis W, Wolfs TFW, Shachor-Meyouhas Y, Stein M, Sanders EAM, Bont LJ. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr;17(4):431-440. doi: 10.1016/S1473-3099(16)30519-9. Epub 2016 Dec 22.</citation>
    <PMID>28012942</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

